IL236685B - Chiral nucleic acid adjuvant

26 members in 13 offices

This recordMember, by publication datePriority claim3 more offices are in the list below

Priority claims
Document	Office	Kind	Date
201261671654	United States of America	P	2012-07-13
201261671654	United States of America	P	2012-07-13
2013069107	Japan	W	2013-07-12
2013069107	Japan	W	2013-07-12
61671654	–	–	–
PCTJP2013069107	–	–	–
US201261671654P	–	–	–
WO2013JP69107	–	–	–

Family members, oldest first
Document	Office	Kind
CA2879066A1	Canada	A1	2014-01-16
WO2014010718A1	World Intellectual Property Organization (WIPO)	A1	2014-01-16
AU2013287630A1	Australia	A1	2015-02-05
IL236685A0	Israel	A0	2015-02-26
IL236685D0	Israel	D0	2015-02-26
KR20150028352A	Republic of Korea	A	2015-03-13
SG11201500243WA	Singapore	A	2015-04-29
EP2873674A1	European Patent Office (EPO)	A1	2015-05-20
CN104684923A	China	A	2015-06-03
MX2015000497A	Mexico	A	2015-06-05
US2015166999A1	United States of America	A1	2015-06-18
EP2873674A4	European Patent Office (EPO)	A4	2016-04-20
JPWO2014010718A1	Japan	A1	2016-06-23
RU2015100198A	Russian Federation	A	2016-08-27
US9617547B2	United States of America	B2	2017-04-11
AU2013287630B2	Australia	B2	2017-05-25
BR112015000723A2	Brazil	A2	2017-06-27
JP6246121B2	Japan	B2	2017-12-13
KR101835401B1	Republic of Korea	B1	2018-03-08
MX356830B	Mexico	B	2018-06-15
CN104684923B	China	B	2018-09-28
RU2677639C2	Russian Federation	C2	2019-01-18
IL236685A	Israel	A	2019-05-30
IL236685BThis record	Israel	B	2019-05-30
CA2879066C	Canada	C	2019-08-13
EP2873674B1	European Patent Office (EPO)	B1	2020-05-06

2 legal events, as the office reported them to INPADOC

Point at a mark for the event

Legal events, newest first
	Event	Code
2019-09-26	Patent grantedGrantedFF	FF
2019-09-26	Patent renewedKB	KB

CPC, 15: A61K39/39
C12N15/117
C07H21/04
A61K2039/55561
A61P11/00
A61P17/02
A61P31/00
A61P35/00
A61P37/00
A61P37/02
A61P37/06
A61P43/00
C12N2310/17
C12N2310/315
C12N15/00
Filled: the office’s first classification

Chiral nucleic acid adjuvant